Emanuel will visit the Broad Institute of MIT and Harvard, where we will work with Dr. John Doench developing novel combinatorial base-editing CRISPR screens. This project aims to identify synergistic genetic interactions that contribute to drug resistance, ultimately uncovering mechanisms that could be targeted for new treatments.

https://www.fulbright.pt/resultados-das-bolsas-fulbright-para-professores-as-e-investigadores-as-com-doutoramento/